Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Filtros aplicados

Base de dados
Intervalo de ano de publicação
1.
Clin. transl. oncol. (Print) ; 8(11): 805-811, nov. 2006. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-126237

RESUMO

BACKGROUND: B-cell chronic lymphocytic leukemia (B-CLL) is a remarkably heterogeneous disorder. Some patients have an indolent disease whereas others undergo a more agressive presentation needing treatment. New therapeutics approaches are necessary for the treatment of B-CLL. Bortezomib (Btz), is a proteasome inhibitor, currently undergoing clinical trials whose function, at least in part, by stabilizing the IkappaBalpha protein and inhibiting NFkappaB activation. OBJECTIVE: The objective of this work was to study the effects of Btz on isolated human B-CLL cells, in vitro, and to correlate the differential rates of apoptosis induction with biological variables. MATERIAL AND METHODS: 31 B-CLL samples, from patients in stage A of Binet were used for this study, and the apoptotic effect of Btz on these cells was measured. RESULTS: Our data show that Btz treatment of B-CLL cells induces apoptosis in a time and dose-dependent manner. The apoptosis induction is mediated in part by inhibition of NFkappaB and is dependent on caspases activation. Interesting, in IgVH mutated cells, Btz have statistically significant differences in their in vitro activity on B-CLL cells according to their BCL-6 mutational status. CONCLUSIONS: Btz is a promising pharmacologic agent for the treatment of B-CLL, but its efficacy seems to be related to IgVH and BCL-6 mutational status, therefore, it could be interesting to further investigate the mechanisms involved in the different behavior of the cells in response to apoptosis induction by this drug (AU)


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , ADP-Ribosil Ciclase 1/biossíntese , ADP-Ribosil Ciclase 1/genética , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacologia , Apoptose , Ácidos Bóricos/administração & dosagem , Ácidos Bóricos/farmacologia , Quinase I-kappa B/antagonistas & inibidores , Proteínas I-kappa B/metabolismo , NF-kappa B/antagonistas & inibidores , Leucemia Linfocítica Crônica de Células B/genética , Leucemia Linfocítica Crônica de Células B/patologia , Proteína-Tirosina Quinase ZAP-70/biossíntese , Proteína-Tirosina Quinase ZAP-70/genética , Nitrilos/farmacologia , Inibidores de Caspase , Caspases/fisiologia , Clorometilcetonas de Aminoácidos/farmacologia , Cadeias Pesadas de Imunoglobulinas/genética , Fosforilação , Células Tumorais Cultivadas , Células Tumorais Cultivadas/metabolismo , Pirazinas/administração & dosagem , Pirazinas/farmacologia , Sulfonas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA